Bronchetamin

Bronchetamin

Butamirate

Symptomatic treatment of dry cough of various etiologies: cough in the preoperative and postoperative period, during surgical interventions, bronchoscopy, whooping cough.

Inside, before eating.

Drops: children from 2 months to 1 year — 10 drops 4 times a day, 1-3 years — 15 drops 4 times a day, older than 3 years-25 drops 4 times a day.

Syrup (measured with a measuring cap): children from 3 to 6 years — 5 ml 3 times a day, 6-12 years-10 ml 3 times a day, 12 years and older-15 ml 3 times a day, adults-15 ml 4 times a day.

The measuring cap should be washed and dried after each use. If the cough persists for more than 7 days, you should consult a doctor.

hypersensitivity to the components of the drug,

pregnancy (first trimester),

lactation period,

children up to 2 months (for drops) and up to 3 years (for syrup).

With caution: pregnancy (II and III trimesters).

When using the drug Bronchetamin^® rarely (≥1/10000, <1/1000) the following side effects are observed.

From the central nervous system: drowsiness, dizziness.

From the gastrointestinal tract: nausea, diarrhea.

From the skin: rash.

Other: rarely-it is possible to develop allergic reactions.

Symptoms: drowsiness, nausea, vomiting, diarrhea, dizziness, and decreased blood pressure.

Treatment: gastric lavage, administration of activated charcoal, maintenance of vital functions of the body. There is no special antidote.

Butamirate, the active substance of the drug Bronchetamin^®, is a central-acting antitussive agent. It does not belong to the opium alkaloids either in terms of chemical structure or pharmacological properties.

Suppresses cough, having a direct effect on the cough center. It has a bronchodilating effect (dilates the bronchi). It helps to facilitate breathing, improving spirometry (reduces the resistance of the respiratory tract) and blood oxygenation (saturates the blood with oxygen).

Butamirate is rapidly and completely absorbed when taken orally. After taking 150 mg of butamirate C_max in the plasma of the main metabolite (2-phenylbutyric acid) is 6.4 mcg/ml and is reached after about 1.5 hours. With repeated administration of the drug, its concentration in the blood remains linear, and no accumulation is observed.

Hydrolysis of butamirate, initially to 2-phenylbutyric acid and diethylaminoethoxyethanol, begins in the blood. These metabolites also have antitussive activity. Like butamirate, the metabolites have an almost maximum (about 95%) degree of binding to plasma proteins, which causes, among other things, their long half-life from plasma. The metabolites are mainly excreted by the kidneys, with acidic metabolites largely associated with glucuronic acid. T_1/2 it is 6 hours.

• Central-acting antitussive agent [Antitussive agents]

No drug interactions for butamirate have been described.